Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the Eur...

Full description

Bibliographic Details
Main Authors: Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, Jennifer O'Sullivan, Deepti Radia, Natalia Curto Garcia, Patrick Harrington, Shahram Kordasti, Susan Asirvatham, Priya Sriskandarajah, Jamie Saunders, Chandan Saha, Irene Sanchez, Hugues deLavallade, Donal P McLornan, Claire N Harrison
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Leukemia Research Reports
Subjects:
MPN
IFN
Essential Thrombocythaemia
Polycythaemia Vera
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048922000711

Internet

http://www.sciencedirect.com/science/article/pii/S2213048922000711

Similar Items